Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ... Biopharmaceuticals, Oncology Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news